Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

CTS-1027 in Interferon-Naive Hepatitis C Patients


A Trial of CTS-1027 in Interferon-Naive Hepatitis C Patients




The study is intended to determine whether CTS-1027 either alone or in combination with ribavirin is safe and effective in Hepatitis C patients who have not previously been treated with interferon.

Study Status: Completed


Condition Intervention Phase
Hepatitis C Drug: ribavirin
Drug: CTS-1027
Drug: Placebo for ribavirin
Phase 2

Verified by Conatus Pharmaceuticals Inc. February, 2012

Sponsored by: Conatus Pharmaceuticals Inc.
Information provided by: Conatus Pharmaceuticals Inc. identifier: NCT00925990

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Erin Castelloe, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site